EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial

Tshilidzi M Klingler, Uwe M Martens, Jorge Riera-Knorrenschild, Swen Wessendorf, Thomas Ettrich, Stephan Kanzler, Sophie Lugani, Elena Rohleder, Arndt Stahler, Alena A Hasenburg, Swantje Held, Petra Buechner-Steudel und 5 weitere

European Journal of Cancer · 2026-10 · 247 · 117045

DOI: 10.1016/j.ejca.2026.117045 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-10. Verfasst von Tshilidzi M Klingler und 16 weiteren Autor:innen. Beteiligte Einrichtung: Klinikum Esslingen, Esslingen, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Quality of Life, Camptothecin. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsQuality of LifeCamptothecinHumansPanitumumabFluorouracilLeucovorinFemaleMiddle AgedOrganoplatinum CompoundsMaleAgedAdultras Proteins

Stichwörter der Autor:innen

FOLFOXIRIMetastatic colorectal cancerPanitumumabQuality of lifeRAS wild-type

Substanzen

PanitumumabFluorouracilLeucovorinOrganoplatinum CompoundsCamptothecinras Proteins

Autor:innen und Institutionen

  • Klinikum Esslingen, Esslingen, Germany.
  • SLK Kliniken Klinikum am Gesundbrunnen, Heilbronn, Germany.
  • Universitätsklinik Marburg, Marburg, Germany.
  • Universitätsklinikum Ulm, Ulm, Germany.
  • Leopoldina Krankenhaus, Schweinfurt, Germany.
  • Charité Comprehensive Cancer Center, Charité Universitätsmedizin Berlin, Berlin, Germany.

Zitieren

APA

Klingler, T. M., Martens, U. M., Riera-Knorrenschild, J., Wessendorf, S., Ettrich, T., Kanzler, S., Lugani, S., Rohleder, E., Stahler, A., Hasenburg, A. A., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Geissler, M., Modest, D. P., & Werner, J. (2026). Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial. European Journal of Cancer, 247, 117045. https://doi.org/10.1016/j.ejca.2026.117045

Vancouver

Klingler TM, Martens UM, Riera-Knorrenschild J, Wessendorf S, Ettrich T, Kanzler S, et al. Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial. European Journal of Cancer. 2026;247:117045. doi:10.1016/j.ejca.2026.117045

BibTeX
@article{Klingler2026,
  author = {Klingler, Tshilidzi M and Martens, Uwe M and Riera-Knorrenschild, Jorge and Wessendorf, Swen and Ettrich, Thomas and Kanzler, Stephan and Lugani, Sophie and Rohleder, Elena and Stahler, Arndt and Hasenburg, Alena A and Held, Swantje and Buechner-Steudel, Petra and Atzpodien, Jens and Heinemann, Volker and Geissler, Michael and Modest, Dominik P and Werner, Johannes},
  title = {Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {247},
  pages = {117045},
  doi = {10.1016/j.ejca.2026.117045}
}
Kostenlos starten →